Clinical trials: Dementia Mild
Alzheimer's Disease
SB-742457 And Donepezil In Alzheimer's Disease
The purpose of this study is to find out if SB-742457 is a safe treatment and what effects it has on the symptoms of mild to moderate Alzheimer's Disease.
- Trial name
- NCT00348192
- Testing
- SB-742457, donepezil
- Where
- 26 sites in Austria, Bulgaria and 6 more
- Volunteers
- 200 people
- Sponsor
- GlaxoSmithKline
Dementia, Alzheimer Type
TRx0014 in Patients With Mild or Moderate Alzheimer's Disease
The primary objective of the study is to investigate the effects of oral TRx0014 at three doses (30, 60 and 100 mg tid) compared with placebo on cognitive ability in patients with mild or moderate dementia of the Alzheimer type.
- Trial name
- NCT00515333
- Testing
- TRx0014
- Volunteers
- 323 people
- Sponsor
- TauRx Therapeutics Ltd
Alzheimer Disease
Study Evaluating Lecozotan SR in Mild to Moderate Alzheimer's Disease (AD)
The purpose of this study is determine the safety, tolerability, and efficacy of 3 doses of lecozotan SR in patients with mild to moderate Alzheimer's Disease over 12 weeks.
- Trial name
- NCT00151398
- Testing
- lecozotan SR, Donepezil
- Where
- 56 sites in United States, Argentina and 3 more
- Volunteers
- 229 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Early Alzheimer's Disease
A Study to Evaluate the Pharmacokinetics of E2609 and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared With Healthy Subjects
The primary objective of the study is to evaluate the effects of hepatic impairment on the pharmacokinetics (PK) of E2609 after a single dose administration.
- Trial name
- NCT02859207
- Testing
- E2609
- Where
- 3 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Eisai Inc.
Alzheimer's Disease, Dementia
A Study Of Oral PF-01913539 In Patients With Mild To Moderate Alzheimer's Disease
The purpose of this study is to demonstrate the safety and efficacy of PF-01913539 in the treatment of patients with mild-to-moderate Alzheimer's Disease.
- Conditions
- Alzheimer's Disease, Dementia, Dimebon, Investigational Drug
- Trial name
- NCT01066481
- Testing
- PF-01913539 5 mg
- Sponsor
- Pfizer
Mild Cognitive Impairment, So Stated
Safety, Tolerability and Efficacy Study to Evaluate Subjects With Mild Cognitive Impairment
The purpose of this study is to find out if different doses of Investigational Drug are safe, tolerable, and if they have an effect on Mild Cognitive Impairment (MCI).
- Trial name
- NCT00422981
- Testing
- AL-108
- Where
- 17 sites in United States
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- Allon Therapeutics
Alzheimer's Disease, Central Nervous System Diseases
Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Alzheimer's Disease
This study is being conducted to determine the safety, tolerability, and pharmacokinetics (PK) of three different doses of an investigational medication, EVP-6124, in individuals with mild to moderate Alzheimer's disease who are…
- Trial name
- NCT00766363
- Testing
- EVP-6124 (0.1 mg/day), EVP-6124 (0.3 mg/day), EVP-6124 (1.0 mg/day)
- Where
- 4 sites in United States
- Volunteers
- 49 people
- Sponsor
- FORUM Pharmaceuticals Inc
Alzheimer's Disease
Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074
To evaluate the safety and tolerability of ascending oral doses of CHF 5074 administered once per day for up to 12 weeks to patients with mild cognitive impairment.
- Trial name
- CT04 (NCT01303744)
- Testing
- CHF 5074 1x, CHF 5074 2x, CHF 5074 3x
- Where
- 9 sites in United States, Italy
- Volunteers
- 96 people
- Sponsor
- CERESPIR
Engagement, Patient, Mood
SimpleC Wellness Platform With Social Robot Interaction
This implementation study will be conducted to test a Socially-Assistive Robot (SAR) system for residents in an Assisted Living environment. The goal of the SAR system is to enhance social engagement and connectedness.
- Conditions
- Engagement, Patient, Mood, Quality of Life, Aging
- Trial name
- NCT05296239
- Testing
- SimpleC Wellness Platform with Social Robot Interaction
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- SimpleC, LLC
Alzheimer Disease
Study to Evaluate the Effect of CT1812 Treatment on Amyloid Beta Oligomer Displacement Into CSF in Subjects With Mild to Moderate Alzheimer's Disease
This is a multi-center, Phase 1b, randomized, double-blind, placebo-controlled parallel-group trial in adults with mild to moderate AD.
- Trial name
- NCT03522129
- Testing
- CT1812
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Cognition Therapeutics
Alzheimer's Disease
Evaluation of Inter-reader Reliability Using Images From Subjects With Alzheimer's Disease (AD) or Mild Cognitive Impairment (MCI)
Re-read of brain amyloid scans acquired in previous AV-45 clinical studies by readers trained using updated reading methodology.
- Trial name
- NCT01565382
- Testing
- florbetapir F 18
- Volunteers
- 40 people
- Sponsor
- Avid Radiopharmaceuticals
Dementia, Alzheimer Type
A Phase II Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to AD (XanADu)
This XanADu Phase II study in mild Alzheimer's Disease (AD) is to assess the safety, tolerability and efficacy of Xanamem in subjects with mild dementia due to Alzheimer's Disease.
- Trial name
- XanADu (NCT02727699)
- Testing
- Xanamem™
- Where
- 25 sites in United States, Australia and 1 more
- Volunteers
- 185 people
- Sponsor
- Actinogen Medical
Alzheimer Disease
A Trial to Evaluate the Efficacy and Safety of PQ912 in Patients With Early AD
This is a Phase 2A multi-center, randomized, double blind, placebo-controlled, parallel group study of varoglutamstat, with a stage gate to Phase 2B.
- Trial name
- VIVA-MIND (NCT03919162)
- Testing
- PQ912
- Where
- 22 sites in United States
- Volunteers
- 112 people
- Sponsor
- Vivoryon Therapeutics N.V.
Alzheimer Disease
A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease
The main purpose of this study is to evaluate the safety of LY3954068 in participants with early symptomatic Alzheimer's Disease (AD).
- Trial name
- NCT06297590
- Testing
- LY3954068, Flortaucipir F18
- Where
- 10 sites in United States, Japan and 1 more
- Volunteers
- 56 people
- Sponsor
- Eli Lilly and Company
Alzheimer Disease
A Study of CM383 in Patients With Alzheimer's Disease Related Mild Cognitive Impairment and Mild Alzheimer's Disease
This is a randomized, double-blind, placebo-controlled and multiple dose escalation phase Ib study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of CM383 in patients with Alzheimer's…
- Trial name
- NCT06619613
- Testing
- Alzheimer Disease (AD)
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Keymed Biosciences Co.Ltd
Alzheimer's Disease
Study to Evaluate the Efficacy and Safety of GSK239512 in Alzheimer's Disease
This study aims to evaluate the cognitive enhancing effects and tolerability of GSK239512 compared to placebo in patients with mild to moderate Alzheimer's disease
- Trial name
- NCT01009255
- Testing
- GSK239512
- Where
- 35 sites in Bulgaria, Chile and 6 more
- Volunteers
- 196 people
- Sponsor
- GlaxoSmithKline
Alzheimer's Disease
Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy For Subjects With Mild To Moderate Alzheimer's Disease
Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose.
- Trial name
- REFLECT-2 (NCT00348309)
- Testing
- Rosiglitazone Extended Release 2mg, Rosiglitazone Extended Release 8mg, Donepezil
- Where
- 249 sites in United States, Argentina and 17 more
- Volunteers
- 1,496 people
- Sponsor
- GlaxoSmithKline
Vascular Cognitive Impairment no Dementia
Mexidol® Efficacy and Safety in Treatment of VCIND in Older Adults
The primary objective of this study is to evaluate the efficacy of Mexidol® sequential parenteral and oral administration as part of comprehensive therapy in older adults with chronic brain ischemia and vascular cognitive…
- Trial name
- NCT07700615
- Testing
- Mexidol, Standard Therapy
- Where
- 4 sites in Russia
- Volunteers
- 120 people
- Sponsor
- Pharmasoft
Alzheimer Disease
Study Evaluating Safety, Tolerability, And Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease
To assess the safety, tolerability, and immunogenicity of ACC-001, an investigational active immunization, in patients with mild to moderate Alzheimer's disease.
- Trial name
- NCT00479557
- Testing
- ACC-001 + QS-21, ACC-001, QS-21
- Where
- 24 sites in France, Germany and 1 more
- Volunteers
- 86 people
- Sponsor
- Pfizer
Alzheimer's Disease
A Study of RO5313534 as Add-on to Donepezil Treatment in Patients With Mild to Moderate Alzheimer's Disease
This 4 arm study will assess the efficacy and safety of RO5313534 (MEM3454) versus placebo added to donepezil, in patients with mild to moderate Alzheimer's disease.
- Trial name
- NCT00884507
- Testing
- RO5313534
- Where
- 67 sites in United States, Argentina and 11 more
- Volunteers
- 389 people
- Sponsor
- Hoffmann-La Roche